LARGE SCALE AUTOMATED DNA SEQUENCING OF HUMAN GENES

此次收购的目标是加快正在进行的遗传 研究以获得诊断、治疗和治疗的关键数据 遗传性神经疾病的预防。承包商将 在最耗费人力、空间和时间的情况下进行基因研究 消耗备战水平。 承包商应尽最大努力高度发展 可重复使用的DNA模板快速生产及纯化 为高度准确提供足够纯度的DNA的程序 自动化DNA序列分析和显著改进的技术 目前用于基因分型和位置克隆。据估计， 承包商将被要求提供大约5000 纯化DNA模板制剂/年，通过生成嵌套式 感兴趣克隆中的缺失；按以下数量进行基因分型 每200个DNA样本/年约有300个标记； 筛选了大约10个图书馆。DNA的来源将是 由NINDS提供给承包商。NINDS DNA设施将 负责对所产生的材料和结果进行评估 由承包商提供。

The objectives of this acquisition are to speed up ongoing genetic research to obtain data critical for diagnosis, treatment and prevention of hereditary neurologic disorders. The Contractor will perform genetic research at the most labor intensive, space and time consuming preparatory level. The Contractor shall exert its best efforts to develop highly reproducible rapid DNA template production and purification procedures which provide DNA of sufficient purity for highly accurate automated DNA sequence analysis and significantly improve techniques currently used for genotyping and positional cloning. It is estimated that the Contractor will be required to provide approximately 5,000 purified DNA template preparations/year by generating nested deletions in clones of interest; perform genotyping in the amount of approximately 300 markers per 200 DNA samples/year; perform screening of approximately 10 libraries. The sources of DNA will be provided to the Contractor by the NINDS. The NINDS DNA Facility will be responsible for evaluation of the materials and results produced by the Contractor.